India covid-19 experts patient India

Covid treatment: Zydus gets SEC nod for clinical trials of antibodies cocktail

Reading now: 226
www.livemint.com

Zydus Cadila has received the permission of the Subject Expert Committee (SEC) to conduct clinical trials of its monoclonal antibodies (mAbs)-based cocktail for the treatment of Covid-19, reported ANI. "SEC gives a recommendation for the phase 1 and 2 clinical trials of Zydus Cadila's biological therapy ZRC-3308, a cocktail of two SARS-CoV-2-neutralising monoclonal antibodies (mAbs) that can emerge as one of the main treatments for mild Covid-19," the news agency quoted a source as saying.ZRC-3308 is a cocktail of two anti-SARS-CoV-2 monoclonal antibodies.

Read more on livemint.com
The website covid-19.rehab is an aggregator of news from open sources. The source is indicated at the beginning and at the end of the announcement. You can send a complaint on the news if you find it unreliable.

Related News

DMCA